US 11479770
Use of p38 inhibitors to reduce expression of DUX4
granted A61KA61K31/00A61K31/416
Quick answer
US patent 11479770 (Use of p38 inhibitors to reduce expression of DUX4) held by Fulcrum Therapeutics, Inc. expires Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Fulcrum Therapeutics, Inc.
- Grant date
- Tue Oct 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 8
- CPC classes
- A61K, A61K31/00, A61K31/416, A61K31/437, A61K31/4418